Alentis Therapeutics
Biologics & Biosimilars · Biotechnology
$181.4Mlatest round · Series D · Nov 2024 · 2 yr ago
5backers · RA Capital Management, High-Tech Gründerfonds
50+team · employees, estimated range
26stories in the press
Overview
THE CLAUDIN-1 COMPANY Treat cancer and reverse fibrosis We are a clinical-stage biotech company with a mission to treat cancer and reverse fibrosis. To this end, we are rapidly advancing our pipeline of anti-Claudin-1 antibody-drug conjugates (ADCs) and monoclonal antibodies.
Key facts
These are the key facts about Alentis Therapeutics on Alion as of Nov 13, 2026. It was founded in 2019. The latest round is Series D of $181.4M, announced in 2024.
- Founded
- 2019Alion company profile, updated Oct 26, 2026
- Employees
- 50+Alion company profile, an estimated range
- Total raised
- $181.4MSum of 1 equity round Alion knows
- Latest round
- Series D · $181.4M · Nov 12, 2024Press report · businesswire.com
Funding and backers
Total raised
$181.4M
1 round on record
Latest round
$181.4M
Series D · Nov 2024 · 2 yr ago
Team
51-200
employees, estimated range
Backers
5
RA Capital Management, High-Tech Gründerfonds
The money's age
Due for its next round
24 months since the last round · not hiring
Momentum
15/100
in the news
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Oct 14
Partnership Swiss firm Alentis Therapeutics partners with Korea's PinotBio to develop next-gen ADCs targeting claudin-1 · biospectrumasia.com
Nov 12, 2024
Raised a round Series D $181.4M · led by OrbiMed · businesswire
2019
Founded
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Series D | Nov 2024 | $181.4M | OrbiMed lead | businesswire |
Backed byfrom the funds' portfolios and accelerator catalogs
Investors in similar startupsfunds that back the companies most like this one
backs Evlabio
Similar startupsby what they do, their industry and backers
Angiex is developing first-in-class Nuclear-Delivered Antibody-Drug Conjugates™ (ND-ADCs) to address the hallmarks of cancer lethality.
Invenra delivers high-quality antibody discovery and engineering solutions, including monoclonal, bispecific, and trispecific antibodies…
AusperBio is a Phase II clinical-stage biopharmaceutical company dedicated to transforming HBV treatment for cure and advancing…
Home Technology Antibody Drug Conjugates Innovative Platform - ‘OptiLinked’ FDCs Additional Products & Applications ANT-045, Antikor’s…
Barinthus Biotherapeutic induces T cells and antibodies to treat and prevent disease.
InCephalo engineers compartment-locked biologics to treat glioblastoma. Our C-Lock™ technology delivers potent immune activation to brain…
Financials
Total raised
$181.4M
Latest round
Series D
Funding rounds
1
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Series D | 2024 | $181.4M | Details |
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
Jeito CapitalVia a fund
Longitude CapitalVia a fund
78 portfolio companies: Zenas BioPharma, Mobia Medical, Inc. and 76 more
OrbiMedVia a fund
196 portfolio companies: Cookiedatabase.org, ZYLOX-TONBRIDGE MEDICAL TECHNOLOGY CO., LTD., Z-Alpha Therapeutics and 193 more
RA Capital ManagementVia a fund
High-Tech GründerfondsVia a fund
517 portfolio companies
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
Shared investors
News
Swiss firm Alentis Therapeutics partners with Korea's PinotBio to develop next-gen ADCs targeting claudin-1
Alentis and PinotBio Announce Collaboration to Develop Next-Generation ADCs Targeting claudin-1
Read more
Report
Alentis and PinotBio announce collaboration to develop next-generation ADCs targeting claudin-1
Basel, Switzerland and Suwon, Korea - Oct 14, 2026 - Alentis Therapeutics and PinotBio today announced they have entered into a research collaboration and licensing agreement to discover and develop next-generation antibody-drug conjugates (ADCs) to expan
Read more
Report
CSL and Alentis announce global partnership to develop and commercialise lixudebart for rare kidney and liver diseases
Alentis to receive US$355 million initial payment and up to US$1.2 billion in commercial milestones, with global profits shared Melbourne, Australia, and Basel, Switzerland - Oct 5, 2026 - CSL and Alentis Therapeutics today announced they have entered int
Read more
Report
Report
Report
Alentis Strengthens Management Team with Key Appointments
Basel, Switzerland - Nov 12, 2025, Alentis Therapeutics ("Alentis"), a clinical-stage biotechnology company developing first-in-class therapies targeting claudin-1 for a range of fibrosis and oncology indications, today announced the appointment of Bryan
Read more
Report
Alentis Appoints Mark Pruzanski as CEO
Basel, Switzerland - Oct 15, 2025, Alentis Therapeutics ("Alentis"), a clinical-stage biotechnology company developing first-in-class therapies targeting claudin-1 for a range of fibrosis and oncology indications, today announced the appointment of Mark P
Read more
Report
Alentis Announces Positive Topline Results from Two Studies of Lixudebart (ALE.F02) in Patients with ANCA-RPGN and Advanced Liver Fibrosis
Robust Dose-Dependent Target Engagement Demonstrated by Lixudebart in Both Studies Preliminary Evidence of Improvement in Organ Function: eGFR and Proteinuria in ANCA-RPGN, and ALT/ AST in Liver Fibrosis Lixudebart Exhibited a Favorable Safety Profile and
Read more
Report
Show more news
How to cite this page
Alion, "Alentis Therapeutics: key facts", as of Nov 13, 2026. https://alion.io/company/alentis
These figures are published under a free licence. You may reuse them, including commercially, as long as you credit Alion and link back to this page. CC BY-SA 4.0